So basically BUBs is scaling to cater for significant growth with its product and manufacturing expenses over the past and next quarter, and your analysis is based on BUBs securing zero additional new deals for the current financial year.
If that occurred BUBs would have definitely failed.
I smell amateurish analysis or continued downramping attempts.
- Forums
- ASX - By Stock
- BUB
- Bubs FY19 $50M
Bubs FY19 $50M, page-9
-
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BUB (ASX) to my watchlist
|
|||||
Last
14.0¢ |
Change
0.005(3.70%) |
Mkt cap ! $124.8M |
Open | High | Low | Value | Volume |
13.5¢ | 14.0¢ | 13.0¢ | $179.2K | 1.328M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 1958180 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
14.0¢ | 961442 | 25 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 1958180 | 0.130 |
51 | 3829215 | 0.125 |
67 | 3909216 | 0.120 |
28 | 1681963 | 0.115 |
34 | 813126 | 0.110 |
Price($) | Vol. | No. |
---|---|---|
0.140 | 961442 | 25 |
0.145 | 521511 | 17 |
0.150 | 1005594 | 31 |
0.155 | 164334 | 10 |
0.160 | 190718 | 11 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
BUB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online